Impact of textbook outcome after hepatectomy for colorectal metastases on salvage curative-intent treatment at recurrence

Table 5 Univariable and multivariable cox regression analyses of factors associated with overall survival

Variables	Univariate		Multivariate
	P value	HR (95%CI)	P value	HR (95%CI)
Gender, male	0.385	0.81 (0.50-1.30)
Age, ≥ 60 years	0.155	1.40 (0.88-2.23)
BMI, ≥ 24 kg/m2	0.601	0.88 (0.55-1.42)
Hypertension	0.263	0.75 (0.46-1.24)
Diabetes	0.630	1.18 (0.60-2.31)
Tumor grade, high	0.136	0.68 (0.41-1.13)
Laparoscopic	0.529	0.85 (0.51-1.41)
Major hepatectomy	0.047	1.97 (1.01-3.86)	0.200	1.58 (0.79-3.18)
Neoadjuvant therapy	0.005	0.49 (0.30-0.80)	0.055	0.60 (0.36-1.01)
Primary tumor location, colon	0.905	0.97 (0.61-1.56)
Lymph nodal metastasis	0.114	1.57 (0.90-2.73)
Synchronous	0.264	1.37 (0.79-2.40)
Multiple	0.351	0.80 (0.50-1.28)
Bilobar	0.338	0.78 (0.47-1.30)
Max diameter, > 3 cm	0.494	1.18 (0.74-1.87)
CEA, ≥ 10 ng/mL	0.114	1.46 (0.91-2.33)
Simultaneous resection	0.007	1.90 (1.19-3.03)	0.167	1.48 (0.85-2.58)
Adjuvant therapy	0.079	0.62 (0.37-1.06)	0.053	0.58 (0.33-1.01)
ASA, class III	0.917	1.04 (0.50-2.17)
TO	< 0.001	0.44 (0.28-0.70)	0.138	0.66 (0.39-1.14)
SCT1 (time-varying)	0.002	0.38 (0.21-0.71)	0.031	0.50 (0.26-0.94)

¹To strictly account for immortal time bias, salvage curative-intent treatment was modeled as a time-dependent covariate in the multivariable Cox regression analysis.

HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; CEA: Carcinoembryonic antigen; ASA: American Society of Anesthesiologists physical status; TO: Textbook outcome; SCT: Salvage curative-intent treatment.